Chiara Costanza Volpi

Dr. Chiara Costanza Volpi

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardy, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2016 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
FPFilippo Pietrantonio
Filippo Pietrantonio
MCM. Caporale
M. Caporale
FMFederica Morano
Federica Morano
MSM. Scartozzi
M. Scartozzi
Annunziata GloghiniAnnunziata Gloghini
Annunziata Gloghini
MBMaria Di Bartolomeo
Maria Di Bartolomeo

Verified
Journal Article
Open access
PDF file
JPJuan Carlos Samamé Pérez-Vargas
Juan Carlos Samamé Pérez-Vargas
PBPamela Biondani
Pamela Biondani
CMClaudia Maggi
Claudia Maggi
MGmanuela gariboldi
manuela gariboldi
Annunziata GloghiniAnnunziata Gloghini
Annunziata Gloghini
FPFilippo Pietrantonio
Filippo Pietrantonio
Mesenchymal-epithelial transition (MET) is a member of a distinct subfamily of heterodimeric receptor tyrosine kinase receptors that specifically binds the hepatocyte growth factor (HGF). Binding to HGF leads to receptor dimerization/multimerization and phosphorylation, resulting in its catalytic activation. MET activation drives the malignant progression of several tumor types, including colorectal cancer (CRC), by promoting signaling cascades that mainly result in alterations of cell motility, survival, and proliferation. MET is aberrantly activated in many human cancers through various mechanisms, including point mutations, gene amplification, transcriptional up-regulation, or ligand autocrine loops. MET promotes cell scattering, invasion, and protection from apoptosis, thereby acting as an adjuvant pro-metastatic gene for many tumor types. In CRC, MET expression confers more aggressiveness and worse clinical prognosis. With all of this rationale, inhibitors that target the HGF/MET axis with different types of response have been developed. HGF and MET are new promising targets to understand the pathogenesis of CRC and for the development of new, targeted therapies.

1 January 2017 in Current Opinion in HIV and AIDS
Verified
Journal Article
Closed access
Antonino CarboneAntonino Carbone
Antonino Carbone
CVChiara Costanza Volpi
Chiara Costanza Volpi
AGAmbra Vittoria Gualeni
Ambra Vittoria Gualeni
Annunziata GloghiniAnnunziata Gloghini
Annunziata Gloghini
The present review summarizes the association of the different histotypes of Epstein-Barr virus (EBV)-associated lymphomas with known genetic lesions and/or oncogenic viruses. A more comprehensive understanding of the complex interplay existing between genetic abnormalities of tumor cells and the viral contribution to the development of EBV-associated lymphomas is pivotal for the development of more effective treatments. Recent evidence indicates that HIV may contribute to lymphomagenesis by acting directly on B lymphocytes as a critical microenvironmental factor. The pathogenesis of EBV-associated lymphomas in patients with HIV infection is considered the result of the concerted action of different factors, mainly including impaired immune surveillance, genetic alterations, and concomitant viral infection (EBV and HIV). Immunodeficiency states usually increase susceptibility to cancer as a result of reduced immune surveillance and enhanced chances for virus-driven oncogenesis. Lymphoma remains the most frequent neoplastic cause of death among patients infected with HIV. Several of the HIV-associated lymphomas are related to EBV infection. EBV-associated lymphomas in patients infected with HIV are heterogeneous, not only pathologically but also in terms of pathogenetic pathways and cellular derivation.

23 July 2015 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
LVLuca Varinelli
Luca Varinelli
DCDario Caccia
Dario Caccia
CVChiara Costanza Volpi
Chiara Costanza Volpi
CCclaudio caccia
claudio caccia
MBMaida De Bortoli
Maida De Bortoli
IBItalia Bongarzone
Italia Bongarzone
Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that is over-expressed in several human neoplastic cells. When MIF binds its receptor (CD74) and co-receptor (CD44), it initiates signaling cascades that orchestrate cell proliferation and survival, and it can directly modulate the activity of AMPK. These activities indicate that MIF potentially regulates cell survival and metabolism. We found that MIF was primarily co-expressed with CD74 in 16 out of 23 papillary thyroid carcinoma (PTC) and in all the 27 available anaplastic thyroid carcinoma (ATC) biopsy samples. MIF and CD74 were co-expressed in TPC-1 and HTC-C3 cell lines. The selective MIF inhibitor, 4-iodo-6-phenylpyrimidine (4-IPP), blocked MIF/CD74 internalization, activated JNK, and dose-dependently inhibited proliferation inducing apoptosis and mitotic cell death. In two CD74-negative cell lines, NIM-1 and K1, 4-IPP treatment partially reduced proliferation. Coordinated MIF and CD74 expression appeared to confer in tumor cells the plasticity necessary to escape cell cycle regulation, metabolic changes, and stress conditions. MIF/CD74 signaling removal made cells susceptible to apoptosis and mitotic cell death. This finding suggests a possible avenue for targeting DNA endoreduplication, thus preventing the proliferation of therapy-resistant cell subpopulations. This study highlights MIF/CD74 axis as an important player in the biology of aggressive thyroid neoplasms.

30 April 2015 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
AGAmbra Vittoria Gualeni
Ambra Vittoria Gualeni
CVChiara Costanza Volpi
Chiara Costanza Volpi
Antonino CarboneAntonino Carbone
Antonino Carbone
Annunziata GloghiniAnnunziata Gloghini
Annunziata Gloghini
MicroRNAs (miRNAs) are small non-coding RNAs that modulate gene expression by binding to complementary sequences on target messenger RNA transcripts. In situ hybridisation (ISH) methods have been applied to the study of miRNA in tissue samples in order to understand which is the source of the miRNA of interest. In this paper, the authors describe a novel semi-automated bright field ISH method to visualise miRNAs in formalin fixed paraffin embedded tissue sections. The relevance of this work resides in the use of 3,3′-diaminobenzidine and peroxidase as the detection method, which provides a good defined deposition within tissues This method, which reveals the cells of origin of specific miRNAs, will enable investigators to further explore the biological role of miRNAs.

1 March 2014 in The American Journal of Pathology
Verified
Journal Article
Closed access
Annunziata GloghiniAnnunziata Gloghini
Annunziata Gloghini
CVChiara Costanza Volpi
Chiara Costanza Volpi
DCDario Caccia
Dario Caccia
AGAmbra Vittoria Gualeni
Ambra Vittoria Gualeni
ACAnna M. Cilia
Anna M. Cilia
IBItalia Bongarzone
Italia Bongarzone